PAH Can Be Identified in SSc Patients Using Exercise Testing, Study Says - Pulmonary Hypertension News

PAH Can Be Identified in SSc Patients Using Exercise Testing, Study Says - Pulmonary Hypertension News

PAH Can Be Identified in SSc Patients Using Exercise Testing, Study Says - Pulmonary Hypertension News

Posted: 02 Dec 2019 12:00 AM PST

Cardiopulmonary exercise testing can improve the ability of an algorithm to identify systemic sclerosis patients who have pulmonary arterial hypertension (PAH), a new study suggests.

The study, "Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis," was published in the journal Rheumatology.

Systemic sclerosis (SSc) is one of the main conditions that predisposes a person to develop PAH. Identifying people with SSc-associated PAH as early as possible is important, because early diagnosis and starting treatment rapidly are predictors of good clinical outcomes in this patient population.

The gold standard for detecting PAH is right heart catheterization (RHC), but this invasive technique involves putting a catheter in a patient's heart, so researchers have tried to come up with ways to identify PAH in a less invasive manner.

In a previously published study, researchers developed an algorithm, called DETECT, with the aim of identifying those with SSc most at risk of PAH. Using RHC as the gold standard to detect PAH, this algorithm was found to be quite good at identifying PAH, but it also had a high (over 50%) false-positive rate, which limits its clinical utility.

In the new study, researchers hypothesized that the predictive power of DETECT could be improved by using cardiopulmonary exercise testing (CPET) — a tool to measure the functionality of the heart and lungs during exercise.

To test this hypothesis, the researchers screened 314 people with SSc over a 30-month period using the DETECT algorithm. PAH-positive individuals were referred for CPET before undergoing RHC.

In total, 54 SSc patients were considered positive for PAH (meaning at higher risk) based on the DETECT criteria. These individuals then underwent CPET, as well as RHC, which was again used as the gold standard. Results showed that 17 of the patients (31.5%) had PAH.

Researchers then used statistical models to identify CPET parameters that were predictive of PAH. They found that the best predictor was the relationship between minute ventilation (VE) and carbon dioxide production (VCO2), termed the VE/VCO2 slope. In simple terms, the VE/VCO2 slope is the ratio between the total amount of air a person moves into and out of the lungs in a minute, and the amount of carbon dioxide that is breathed out after transporting oxygen through the body.

The VE/VCO2 slope had a sensitivity of 1.0 in 87% of the models tested — that is, it correctly identified all individuals with PAH 87% of the time. The median specificity — meaning how well the test identifies patients who do not have PAH — was 0.778.

Based on the results, the team stated that "in association with the DETECT algorithm, CPET may be considered as a useful tool in the workup of SSc-related pulmonary hypertension."

"The sequential determination of the VE/VCO2 slope in DETECT-positive subjects may reduce the number of unnecessary invasive procedures without any loss in the capability to capture PAH," the researchers added.

  • Author Details
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 329
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts

Comments

Post a Comment

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Image
Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves...
Read more

Analysis: Large pharma companies do little new drug innovation - STAT

Image
Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the...
Read more